Menopause has a textbook definition: 12 consecutive months without a menstrual period. In theory, no test is required. In practice, the picture is rarely that clean.
Women on hormonal contraception cannot track their cycles. Women under 50 with symptoms may have a thyroid disorder, not menopause. Women who have had a hysterectomy have no period to monitor. And women in perimenopause — the years-long transition before the final period — often need lab confirmation to understand where they are in the process and what treatment is appropriate.
This is where testing comes in. Below are the 8 tests doctors use to confirm menopause, rule out conditions that mimic it, and assess the health risks that low estrogen introduces over time.
1. FSH — Follicle-Stimulating Hormone
What it measures:Â FSH is produced by the pituitary gland to stimulate the ovaries to produce eggs. As the ovaries become less responsive with age, the pituitary releases more and more FSH in an attempt to compensate. Elevated FSH is the most commonly ordered marker for menopause.
What the results mean:
- FSH below 10 mIU/mL: premenopausal range
- FSH between 10 and 20 mIU/mL: early perimenopause
- FSH above 25 to 30 mIU/mL: consistent with perimenopause or menopause
- FSH above 40 mIU/mL: strongly indicates menopause
Critical limitation: FSH fluctuates significantly during perimenopause. A single elevated result does not confirm menopause — levels can be elevated one month and normal the next. Doctors typically require two elevated readings at least one month apart, combined with clinical symptoms and absent periods, before drawing conclusions.
2. Estradiol (E2) — Estrogen Level
What it measures:Â Estradiol is the primary form of estrogen produced by the ovaries. Its blood level reflects current ovarian output and declines steadily as menopause approaches.
What the results mean:
- Estradiol above 30 pg/mL: typically premenopausal
- Estradiol below 20 pg/mL: consistent with menopause
- Estradiol below 10 pg/mL: postmenopausal range
How it’s used: Estradiol is rarely used alone for diagnosis. It is most useful in combination with FSH — a high FSH paired with low estradiol provides stronger confirmation than either value alone. It is also used to monitor hormone therapy dosing once treatment has begun.
3. AMH — Anti-Müllerian Hormone
What it measures: AMH is produced directly by the small follicles remaining in the ovaries. Unlike FSH and estradiol, it does not fluctuate significantly within a menstrual cycle, making it one of the most stable and reliable markers of ovarian reserve — the number of eggs remaining.
What the results mean:
- AMH above 1.0 ng/mL: adequate ovarian reserve
- AMH between 0.5 and 1.0 ng/mL: low reserve, consistent with late perimenopause
- AMH below 0.2 ng/mL: very low reserve, approaching or in menopause
- AMH undetectable: consistent with menopause
Why it matters: AMH is considered more predictive of the final menstrual period than FSH or estradiol. Research published in Menopause (the journal of the North American Menopause Society) shows that undetectable AMH predicts the final period within one to two years with high accuracy. It is particularly useful for women with irregular cycles who cannot rely on period tracking alone.
4. LH — Luteinizing Hormone
What it measures:Â Like FSH, LH is produced by the pituitary gland and rises as the ovaries become less responsive. LH triggers ovulation in premenopausal women. In menopause, elevated LH alongside elevated FSH provides additional hormonal confirmation.
What the results mean:
- LH above 20 to 30 IU/L in a non-ovulatory context: consistent with menopause
- LH is most useful when interpreted alongside FSH and estradiol rather than as a standalone marker
How it’s used:Â LH is not always ordered separately but may be included in a full hormonal panel when the clinical picture is unclear or when FSH alone is borderline.
5. Thyroid Panel — TSH, Free T3, Free T4
What it measures:Â The thyroid panel assesses thyroid function. Both hypothyroidism (underactive thyroid) and hyperthyroidism (overactive thyroid) produce symptoms that closely resemble perimenopause: fatigue, mood changes, weight gain or loss, irregular periods, sleep disruption, brain fog, and heat intolerance.
Why it’s essential: Thyroid disorders affect approximately 1 in 8 women over 40 — the same demographic entering perimenopause. A woman with undiagnosed hypothyroidism may be told she is perimenopausal when thyroid treatment alone would resolve her symptoms. Ruling out thyroid dysfunction is a standard step before attributing symptoms to menopause.
What the results mean:Â TSH above 4.5 mIU/L suggests hypothyroidism; TSH below 0.4 mIU/L suggests hyperthyroidism. Both require separate evaluation and treatment.
6. Complete Blood Count (CBC)
What it measures:Â A CBC evaluates red blood cells, white blood cells, and platelets. In the context of menopause evaluation, it primarily screens for anemia caused by heavy or prolonged perimenopausal bleeding.
Why it matters: Heavy bleeding is common during perimenopause as hormonal fluctuations disrupt the normal uterine cycle. Significant blood loss over multiple cycles can produce iron-deficiency anemia — causing fatigue, weakness, and shortness of breath that compounds menopausal symptoms. Identifying and treating anemia is an important step in symptom management during the transition.
7. DEXA Scan — Bone Density Test
What it measures:Â Dual-energy X-ray absorptiometry (DEXA) measures bone mineral density at the hip and lumbar spine, producing a T-score that compares bone density against a young healthy adult baseline.
T-score interpretation:
- Above -1.0: normal bone density
- Between -1.0 and -2.5: osteopenia (low bone mass)
- Below -2.5: osteoporosis
Why it’s ordered at menopause:Â Estrogen is the primary protective hormone for bone. Women lose an estimated 10% to 20% of bone density in the first five years after menopause. The North American Menopause Society recommends a baseline DEXA scan at menopause for all women, and earlier for those with risk factors including low body weight, smoking history, or family history of osteoporosis. This test does not confirm menopause but assesses its most consequential long-term effect.
8. Transvaginal Ultrasound
What it measures:Â A transvaginal ultrasound allows direct visualization of the ovaries and uterus. It is used to assess two specific markers: the antral follicle count (the number of small resting follicles visible in the ovaries) and the endometrial thickness.
What it shows:
- A low antral follicle count (fewer than 5 to 7 total follicles) correlates with low ovarian reserve and approaching menopause
- Endometrial thickness greater than 4 mm in a postmenopausal woman requires further investigation — it can indicate endometrial hyperplasia or, in some cases, malignancy
- Postmenopausal bleeding is always investigated with transvaginal ultrasound as the first-line imaging tool
How it’s used:Â Ultrasound is not a routine diagnostic test for menopause confirmation but is standard when postmenopausal bleeding occurs or when other imaging of the reproductive organs is clinically indicated.
How These Tests Work Together
No single test confirms menopause in isolation. The diagnosis is made by combining clinical history (period absence for 12 months), symptom profile, age, and lab results. In women under 45 or in ambiguous clinical situations, FSH, estradiol, AMH, and a thyroid panel together provide the clearest picture. DEXA and transvaginal ultrasound are used for health monitoring and specific indications rather than diagnosis.
When to Ask for Testing
Request hormonal testing if: you are under 50 and experiencing menopausal symptoms; you are on hormonal contraception and cannot track your cycles; you have had a hysterectomy and need hormonal status clarified; or your symptoms have not responded to treatment and your diagnosis is uncertain.
This article is for informational purposes only and does not replace professional medical advice. Lab results should always be interpreted by a licensed healthcare provider in the context of your full medical history and clinical presentation.
